Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.
暂无分享,去创建一个
S. Durinck | A. Dutt | W. DeGrado | R. Bueno | E. Sokol | S. Seshagiri | James Ziai | B. Jaiswal | S. Trabucco | M. Mravic | K. Senger | N. Jura | N. Kljavin | E. Stawiski | Subhra Chaudhuri | Kanika Bajaj Pahuja | Thong T. Nguyen | K. Prabhash | R. Hartmaier | V. Noronha | V. Patil | A. Joshi | Sameer Phalke | Ravi Gupta | Aju Antony | Prasanna Kumar | T. Thaker | A. Chougule | Noelyn M. Kljavin | A. Khanna-Gupta | Vaishakhi Trivedi | Ashish Singh | Derek Vargas | V. Ramprasad | S. Banavali
[1] J. Flowers,et al. Origins and geographic diversification of African rice (Oryza glaberrima) , 2018, bioRxiv.
[2] L. Gianni. Is there room for another HER2-targeting drug? , 2018, The Lancet Oncology.
[3] B. Taylor,et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers , 2018, Nature.
[4] Doron Lipson,et al. High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. , 2017, Cancer research.
[5] Vamsidhar Velcheti,et al. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo‐ and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] K. Haustermans,et al. Gastric cancer , 2016, The Lancet.
[7] P. Stephens,et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies , 2016, Cancer.
[8] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[9] R. Bose,et al. HER2 missense mutations have distinct effects on oncogenic signaling and migration , 2015, Proceedings of the National Academy of Sciences.
[10] Gabor T. Marth,et al. A global reference for human genetic variation , 2015, Nature.
[11] Ron Bose,et al. HER2 activating mutations are targets for colorectal cancer treatment. , 2015, Cancer discovery.
[12] J. Kuriyan,et al. A structural perspective on the regulation of the epidermal growth factor receptor. , 2015, Annual review of biochemistry.
[13] Y. Ung,et al. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. , 2015, Current oncology.
[14] Venkatesh Mysore,et al. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations , 2014, Science Signaling.
[15] D. Leahy,et al. Kinase Activator-Receiver Preference in ErbB Heterodimers Is Determined by Intracellular Regions and Is Not Coupled to Extracellular Asymmetry* , 2014, The Journal of Biological Chemistry.
[16] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[17] Guillermo A. Gomez,et al. Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor , 2014, Science.
[18] J. Soh,et al. Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] R. Stroud,et al. Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer , 2014, Proceedings of the National Academy of Sciences.
[20] J. Soh,et al. Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas , 2013, Journal of the National Cancer Institute.
[21] G. MacBeath,et al. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. , 2013, The American journal of pathology.
[22] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[23] Mauricio O. Carneiro,et al. From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.
[24] Jing Huang,et al. CHARMM36 all‐atom additive protein force field: Validation based on comparison to NMR data , 2013, J. Comput. Chem..
[25] Somasekar Seshagiri,et al. Oncogenic ERBB3 mutations in human cancers. , 2013, Cancer cell.
[26] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[27] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[28] D. Shaw,et al. Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor , 2013, Cell.
[29] Anton Arkhipov,et al. Architecture and Membrane Interactions of the EGF Receptor , 2013, Cell.
[30] R. Koeppe,et al. Buried lysine, but not arginine, titrates and alters transmembrane helix tilt , 2013, Proceedings of the National Academy of Sciences.
[31] C. Eng,et al. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. , 2013, American journal of human genetics.
[32] Wendy Winckler,et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 , 2012, Proceedings of the National Academy of Sciences.
[33] Charles R. Sanders,et al. The Amyloid Precursor Protein Has a Flexible Transmembrane Domain and Binds Cholesterol , 2012, Science.
[34] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[35] H. Stern. Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges , 2012, Science Translational Medicine.
[36] T. Ulmer,et al. Snorkeling Basic Amino Acid Side Chains Regulate Transmembrane Integrin Signalling , 2011, Nature.
[37] Hyeon Joo,et al. OPM database and PPM web server: resources for positioning of proteins in membranes , 2011, Nucleic Acids Res..
[38] Jamie K Teer,et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. , 2011, The New England journal of medicine.
[39] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[40] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[41] Shigeyuki Yokoyama,et al. Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor , 2010, Molecular and Cellular Biology.
[42] R. Koeppe,et al. Charged or Aromatic Anchor Residue Dependence of Transmembrane Peptide Tilt* , 2010, The Journal of Biological Chemistry.
[43] W. DeGrado,et al. Transmembrane polar interactions are required for signaling in the Escherichia coli sensor kinase PhoQ , 2010, Proceedings of the National Academy of Sciences.
[44] Robert Gentleman,et al. ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data , 2009, Bioinform..
[45] J. Baselga,et al. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.
[46] V. Grantcharova,et al. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.
[47] A. Pozzi,et al. The juxtamembrane region of the EGF receptor functions as an activation domain. , 2009, Molecular cell.
[48] John Kuriyan,et al. Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.
[49] M J Harvey,et al. ACEMD: Accelerating Biomolecular Dynamics in the Microsecond Time Scale. , 2009, Journal of chemical theory and computation.
[50] Roman G. Efremov,et al. Spatial Structure of the Dimeric Transmembrane Domain of the Growth Factor Receptor ErbB2 Presumably Corresponding to the Receptor Active State* , 2008, Journal of Biological Chemistry.
[51] Carlos L Arteaga,et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.
[52] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[53] R. Hennekam,et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome , 2006, Nature Genetics.
[54] Gayatry Mohapatra,et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR , 2005, Nature Genetics.
[55] H. Lane,et al. ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.
[56] E. Andrechek,et al. Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[57] Jayanta Debnath,et al. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.
[58] T. Springer,et al. The critical cytoplasmic regions of the αL/β2 integrin in Rap1-induced adhesion and migration , 2003 .
[59] Sarel J. Fleishman,et al. A putative molecular-activation switch in the transmembrane domain of erbB2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[60] Tudor Savopol,et al. Molecular basis of transmembrane signalling by sensory rhodopsin II–transducer complex , 2002, Nature.
[61] M. Bissell,et al. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini , 2001, Nature Cell Biology.
[62] A. Berezov,et al. HER2/Neu: mechanisms of dimerization/oligomerization , 2000, Oncogene.
[63] A. N. Meyer,et al. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. , 2000, Molecular biology of the cell.
[64] M. Gerstein,et al. Statistical analysis of amino acid patterns in transmembrane helices: the GxxxG motif occurs frequently and in association with beta-branched residues at neighboring positions. , 2000, Journal of molecular biology.
[65] Berk Hess,et al. Improving efficiency of large time‐scale molecular dynamics simulations of hydrogen‐rich systems , 1999, Journal of computational chemistry.
[66] D. Engelman,et al. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation , 1997, Oncogene.
[67] T. van Raaij,et al. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.
[68] D. Engelman,et al. A dimerization motif for transmembrane α–helices , 1994, Nature Structural Biology.
[69] W. Gullick,et al. Neu receptor dimerization , 1989, Nature.
[70] Cori Bargmann,et al. Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.
[71] Cori Bargmann,et al. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.
[72] R. Weinberg,et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. , 1985, Science.
[73] H. Berendsen,et al. Molecular dynamics with coupling to an external bath , 1984 .
[74] S. Heinemann,et al. Clonal cell lines from the rat central nervous system , 1974, Nature.
[75] N. Socci,et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.
[76] R. Roskoski. The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.
[77] Carlos L. Arteaga,et al. Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.
[78] K. Hristova,et al. A Look at Arginine in Membranes , 2010, The Journal of Membrane Biology.
[79] Berk Hess,et al. Improving Efficiency of Large Time-Scale Molecular Dynamics Simulations of Hydrogen-Rich Systems , 1999 .